Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
The Scientist and Illumina | May 15, 2023 | 4 min read
A conversation with Illumina Distinguished Scientist and Vice President Gary Schroth about the present and future of multiomic technology and applications